BridgeBio Pharma (BBIO) Divestments (2021 - 2025)

BridgeBio Pharma (BBIO) reported Divestments of $2.3 million for Q3 2025, down 91.04% sequentially from $25.7 million in Q1 2024.

BridgeBio Pharma (BBIO) Divestments (2021 - 2025) Analysis & Trends

BridgeBio Pharma (BBIO) has 3 years of Divestments data on file, last reported at $2.3 million in Q3 2025.

For the quarter ending Q3 2025, Divestments changed N/A year-over-year to $2.3 million; the trailing twelve-month figure through Dec 2025 stood at $2.3 million (down 91.04% YoY), and the FY2025 full-year result was $2.3 million, down 91.04% from the prior year.
Divestments eased to $2.3 million in Q3 2025, from $25.7 million in the prior quarter.
In the past five years, Divestments ranged from a high of $29.4 million in Q4 2021 to a low of $2.3 million in Q3 2025.
A 3-year average of $19.1 million and a median of $25.7 million in 2024 frame the typical range for Divestments.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Divestments (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-32.58 Mn
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	-
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	BridgeBio Pharma	16.15 Bn	15.22 Bn	184.58 Mn	-

Download Data